0001127602-18-025142.txt : 20180810
0001127602-18-025142.hdr.sgml : 20180810
20180810180336
ACCESSION NUMBER: 0001127602-18-025142
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20180802
FILED AS OF DATE: 20180810
DATE AS OF CHANGE: 20180810
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: McKenna Mark C.
CENTRAL INDEX KEY: 0001749623
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14956
FILM NUMBER: 181009934
MAIL ADDRESS:
STREET 1: 400 SOMERSET CORPORATE BOULEVARD
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Bausch Health Companies Inc.
CENTRAL INDEX KEY: 0000885590
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: NJ
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2150 ST. ELZEAR BLVD. WEST
STREET 2: LAVAL
CITY: QUEBEC
STATE: A8
ZIP: H7L 4A8
BUSINESS PHONE: 514-744-6792
MAIL ADDRESS:
STREET 1: 2150 ST. ELZEAR BLVD. WEST
STREET 2: LAVAL
CITY: QUEBEC
STATE: A8
ZIP: H7L 4A8
FORMER COMPANY:
FORMER CONFORMED NAME: Valeant Pharmaceuticals International, Inc.
DATE OF NAME CHANGE: 20100928
FORMER COMPANY:
FORMER CONFORMED NAME: BIOVAIL Corp
DATE OF NAME CHANGE: 20100416
FORMER COMPANY:
FORMER CONFORMED NAME: BIOVAIL CORP INTERNATIONAL
DATE OF NAME CHANGE: 19960522
3
1
form3.xml
PRIMARY DOCUMENT
X0206
3
2018-08-02
0
0000885590
Bausch Health Companies Inc.
BHC
0001749623
McKenna Mark C.
400 SOMERSET CORPORATE BLVD.
BRIDGEWATER
NJ
08807
1
President, Salix
Common Shares, No Par Value
21131
D
Restricted Share Units
2020-01-06
Common Shares, No Par Value
2987
D
Restrcited Share Units
2021-03-20
Common Stock, No Par Value
2842
D
Non-qualified Stock Options (right To Purchase)
15.32
2028-03-07
Common Shares, No Par Value
25357
D
Non-qualified Stock Options (right To Purchase)
14.38
2027-03-01
Common Shares, No Par Value
22002
D
Non-qualified Stock Options (right To Purchase)
23.92
2026-06-09
Common Shares, No Par Value
16780
D
Non-qualified Stock Options (right To Purchase)
129.22
2024-05-30
Common Shares, No Par Value
6387
D
Restricted Share Units
Common Shares, No Par Value
712
D
Includes (i) 4,235 restricted share units ("RSUs") which will vest on June 22, 2019, subject to the reporting person's continued service, and (ii) 16,672 RSUs which vest in equal installments on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in Common Shares, no par value ("Common Shares") of Bausch Health Companies Inc. ("Bausch Health").
Represents a grant of performance-based RSUs. The target number of performance-based RSUs granted to the reporting person was 2,987 and the maximum number that can be distributed is 5,974. The performance-based RSUs shall vest and be distributed between 0-200% of target based on TSR as measured on January 6, 2020 (the "2020 Measurement Date"). If the TSR for the period between the grant date and the 2020 Measurement Date is below the 50th percentile ranking of the TSR for the applicable peer group, the reporting person will receive no more than the number of Common Shares equal to the target number of performance-based RSUs subject to the award.
Represents a grant of performance-based RSUs. The target number of performance-based RSUs granted to the reporting person was 2,842 and the maximum number that can be distributed is 4,964. The performance-based RSUs shall vest and be distributed between 0-200% of target based on TSR as measured for the 20 trading days preceding the TSR Measurement Date (the "2021 Measurement Date") which is the third anniversary of the grant date (March 7, 2021). If the TSR for the period between the grant date and the 2021 Measurement Date is below the 50th percentile ranking of the TSR for the applicable peer group based on the 20 trading days preceding the Measurement Date, the reporting person will receive no more than the number of Common Shares equal to the target number of performance-based RSUs subject to the award.
Vests in equal installments on each of the first three anniversaries of the date of grant.
Vests in equal installments on each of the first four anniversaries of the date of grant.
The performance-based RSUs are eligible to vest on the achievement of Bausch Health's Total Shareholder Return ("TSR") target on August 18, 2018, subject to the reporting person's continued service on such date.
Each RSU represents a contingent right to receive between zero and three Common Shares, subject to performance based vesting criteria.
/s/ Kirsten O'Donnell, attorney-in-fact for Mark C. McKenna
2018-08-10
EX-24
2
doc1.txt
POWER OF ATTORNEY (PUBLIC):
POWER OF ATTORNEY
Know all by these presents that the undersigned hereby constitutes and appoints
each of Christina Ackermann, Kelly Webber, D. Alexander Matheson, and
Kirsten O'Donnell, or any of them signing singly, and with full power
of substitution, the undersigned's true and lawful attorney-in-fact to:
(1) prepare, execute in the undersigned's name and on the undersigned's behalf,
and submit to the U.S. Securities and Exchange Commission (the "SEC") a
Form ID, including amendments thereto, and any other documents necessary or
appropriate to obtain codes and passwords enabling the undersigned to make
electronic filings with the SEC of reports required by Section 16(a) of the
Securities Exchange Act of 1934 (the "Exchange Act") or any rule or regulation
of the SEC;
(2) execute for and on behalf of the undersigned, in the undersigned's capacity
as a director and/or officer of Valeant Pharmaceuticals International, Inc.
(the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the
Exchange Act and the rules thereunder;
(3) do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such Form 3, 4, or 5,
complete and execute any amendment or amendments thereto, and timely file
such form with the SEC and any stock exchange or similar authority; and
(4) take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit
to, in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of
the undersigned pursuant to this Power of Attorney shall be in such form and
shall contain such terms and conditions as such attorney-in-fact may approve
in such attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the
rights and powers herein granted, as fully to all intents and purposes as the
undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this power of attorney and the
rights and powers herein granted. The undersigned acknowledges that the
foregoing attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with
respect to the undersigned's holdings of and transactions in securities
issued by the Company, unless earlier revoked by the undersigned in a signed
writing delivered to the foregoing attorneys-in-fact.
[REMAINDER OF PAGE LEFT BLANK INTENTIONALY]
IN WITNESS WHEREOF, the undersigned has caused this Power of
Attorney to be executed as of this 7th of August, 2018.
/s/ Mark C. McKenna
Signature
Mark C. McKenna
Name